Hjem › Akut bifenoypisk leukemi › North Carolina › Winston-Salem
Kliniske studier for Akut bifenoypisk leukemi i Winston-Salem, NC
3 studier for Akut bifenoypisk leukemi søker deltakere på steder i og rundt Winston-Salem (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
- Wake Forest University Health Sciences, Winston-Salem
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
- Wake Forest University Health Sciences, Winston-Salem
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Wake Forest University Health Sciences, Winston-Salem
Akut bifenoypisk leukemi-studier i andre byer
- Seattle, WA15 studier
- Houston, TX11 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Baldwin Park, CA6 studier
- Aurora, CO6 studier
- Dallas, TX6 studier
- Philadelphia, PA6 studier
Andre studier i Winston-Salem
- Kreft (alle typer)19 studier
- Akut myelogen leukemi18 studier
- Multipelt myelom14 studier
- Brystkreft14 studier
- Kardiovaskulær sykdom14 studier
- Ikke-småcellet lungekreft12 studier
- KOLS10 studier
- Eggstokkreft10 studier
- Type 2-diabetes9 studier
- Myelodysplastiske syndromer9 studier
- Glioblastom8 studier
- Kronisk lymfatisk leukemi8 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.